Published in Virology on March 21, 2007
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell (2011) 1.02
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene (1985) 213.67
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol (1981) 15.59
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology (1980) 2.07
Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture. J Virol (1992) 2.02
The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. Cell (1994) 1.90
HIV: current opinion in escapology. Curr Opin Microbiol (2002) 1.86
Dissociation of Rb-binding and anchorage-independent growth from immortalization and tumorigenicity using SV40 mutants producing N-terminally truncated large T antigens. Virology (1990) 1.77
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol (1998) 1.47
Amplification and rearrangement of integrated SV40 DNA sequences accompany the selection of anchorage-independent transformed mouse cells. Cell (1980) 1.38
The transforming activity of simian virus 40 large tumor antigen. Biochim Biophys Acta (1994) 1.32
Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones. J Immunol (1983) 1.29
In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol (1988) 1.29
Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest (2003) 1.28
Immortalization of primary mouse embryo fibroblasts with SV40 virions, viral DNA, and a subgenomic DNA fragment in a quantitative assay. Virology (1984) 1.24
Expression of H-2Db on the cell surface in the absence of detectable beta 2 microglobulin. J Exp Med (1984) 1.23
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol (1997) 1.20
Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol (1995) 1.18
CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med (1992) 1.17
Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo? Immunol Rev (1998) 1.17
In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol (2003) 1.14
Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology (1988) 1.10
An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 1.09
Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J Exp Med (1992) 1.07
Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants. J Immunol (2001) 1.03
Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J Immunol (1995) 1.03
Regulation of class I-restricted epitope processing by local or distal flanking sequence. J Immunol (1997) 1.01
Instability of integrated viral DNA in mouse cells transformed by simian virus 40. Proc Natl Acad Sci U S A (1981) 1.01
Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol (1996) 1.00
Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease. J Virol (1992) 0.99
In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes. J Virol (1996) 0.98
Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol (1999) 0.96
Comparative analysis of core amino acid residues of H-2D(b)-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J Virol (1992) 0.96
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res (1998) 0.95
Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology (1989) 0.95
Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. Virology (1995) 0.94
Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res (2000) 0.93
Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med (1996) 0.93
Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology (1990) 0.89
Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J Immunol (2001) 0.88
Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol (1995) 0.85
A dominant V beta bias in the CTL response after HSV-1 infection is determined by peptide residues predicted to also interact with the TCR beta-chain CDR3. Mol Immunol (1998) 0.84
Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol (2006) 0.83
Immune response to the immunodominant epitope of mouse hepatitis virus is polyclonal, but functionally monospecific in C57Bl/6 mice. Virology (1999) 0.83
Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV. Dev Biol Stand (1998) 0.82
In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J Virol (2004) 0.82
Localization of common cytotoxic T lymphocyte recognition epitopes on simian papovavirus SV40 and human papovavirus JC virus T antigens. Virology (1991) 0.79
Efficient chromosomal mapping of a methylcholanthrene-induced tumor antigen by CTL immunoselection. J Immunol (2001) 0.78
Context-dependent immunogenicity of an S206G-substituted H-2Db-restricted simian virus 40 large T antigen epitope I variant. J Immunol (1999) 0.78
Role of CTL host responses and their implication for tumorigenicity testing and the use of tumour cells as vaccine substrate. Dev Biol (Basel) (2001) 0.77
Indigenous health part 2: the underlying causes of the health gap. Lancet (2009) 4.22
Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol (2004) 2.58
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr (2014) 1.96
Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother (2003) 1.69
Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol (2004) 1.46
IL-10 expression profiling in human monocytes. J Leukoc Biol (2002) 1.40
Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol (2003) 1.38
In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol (2003) 1.14
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst (2002) 1.03
The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunol (2003) 0.98
Invasion of Lotus japonicus root hairless 1 by Mesorhizobium loti involves the nodulation factor-dependent induction of root hairs. Plant Physiol (2005) 0.98
Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol (2005) 0.94
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis (2008) 0.93
Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol (2005) 0.92
Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. J Immunol (2007) 0.88
Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol (2009) 0.87
CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol (2008) 0.86
Drosophila melanogaster Dis3 N-terminal domains are required for ribonuclease activities, nuclear localization and exosome interactions. Nucleic Acids Res (2010) 0.84
Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol (2006) 0.83
Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Front Physiol (2011) 0.83
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82
Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdom Imaging (2009) 0.82
CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol (2012) 0.81
An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology (2008) 0.81
The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. Int Immunol (2002) 0.80
Design of a multi-dopamine-modified polymer ligand optimally suited for interfacing magnetic nanoparticles with biological systems. Langmuir (2014) 0.79
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther (2010) 0.79
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79
Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. J Vaccines Vaccin (2010) 0.78
Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. J Immunol (2010) 0.78
Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther (2010) 0.76
Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. Comp Med (2013) 0.76
The experience of interdisciplinary peer-assisted learning (PAL). Clin Teach (2012) 0.76
Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environ Health Perspect (2006) 0.75
Stabilizing behavior of soy soluble polysaccharide or high methoxyl pectin in soy protein isolate emulsions at low pH. J Agric Food Chem (2006) 0.75
Hybrid cavity-coupled plasmonic biosensors for low concentration, label-free and selective biomolecular detection. Opt Express (2016) 0.75
Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Dig Dis Sci (2008) 0.75
Mechanical and microstructural properties of "wet" alginate and composite films containing various carbohydrates. J Food Sci (2014) 0.75